2023 ESC Guidelines for the management of cardiomyopathies: Developed by the task force on the management of cardiomyopathies of the European Society of …
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …
off-label use of medication should be limited to situations where it is in the patient's interest …
2024 AHA/ACC/AMSSM/HRS/PACES/SCMR guideline for the management of hypertrophic cardiomyopathy: a report of the American Heart Association/American …
Writing Committee Members, SR Ommen… - Journal of the American …, 2024 - jacc.org
Abstract Aim The “2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the
Management of Hypertrophic Cardiomyopathy” provides recommendations to guide …
Management of Hypertrophic Cardiomyopathy” provides recommendations to guide …
Diagnosis and Evaluation of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review
Hypertrophic cardiomyopathy (HCM) is a relatively common often inherited global heart
disease, with complex phenotypic and genetic expression and natural history, affecting both …
disease, with complex phenotypic and genetic expression and natural history, affecting both …
Phase 2 study of aficamten in patients with obstructive hypertrophic cardiomyopathy
Background Left ventricular outflow tract (LVOT) obstruction is a major determinant of heart
failure symptoms in obstructive hypertrophic cardiomyopathy (oHCM). Aficamten, a next-in …
failure symptoms in obstructive hypertrophic cardiomyopathy (oHCM). Aficamten, a next-in …
2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American …
The recommendations listed in this guideline are, whenever possible, evidence based. An
initial extensive evidence review, which included literature derived from research involving …
initial extensive evidence review, which included literature derived from research involving …
2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: executive summary: a report of the American College of …
Aim This executive summary of the hypertrophic cardiomyopathy clinical practice guideline
provides recommendations and algorithms for clinicians to diagnose and manage …
provides recommendations and algorithms for clinicians to diagnose and manage …
Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy
E Braunwald, S Saberi, TP Abraham… - European Heart …, 2023 - academic.oup.com
Mavacamten is a first-in-class, targeted, cardiac-specific myosin inhibitor approved by the
US Food and Drug Administration for the treatment of adults with symptomatic New York …
US Food and Drug Administration for the treatment of adults with symptomatic New York …
Clinical course and management of hypertrophic cardiomyopathy
BJ Maron - New England Journal of Medicine, 2018 - Mass Medical Soc
Hypertrophic Cardiomyopathy HCM is the most common genetic disorder of the heart, with 1
case per 200 to 500 persons, and often remains clinically silent. HCM is the most common …
case per 200 to 500 persons, and often remains clinically silent. HCM is the most common …
Hypertrophic cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy
Hypertrophic cardiomyopathy (HCM) is a genetic disorder that is characterized by left
ventricular hypertrophy unexplained by secondary causes and a nondilated left ventricle …
ventricular hypertrophy unexplained by secondary causes and a nondilated left ventricle …
Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology
Cardiomyopathies are a heterogeneous group of heart muscle diseases and an important
cause of heart failure (HF). Current knowledge on incidence, pathophysiology and natural …
cause of heart failure (HF). Current knowledge on incidence, pathophysiology and natural …